+357 96 030922
info@marketpublishers.com

NSCLC [2016]: Bulletin #3

https://marketpublishers.com/r/N88BE3D6589EN.html
Date: May 2017
Pages: 0
Price: US$ 1,045.00 (Single User License)
ID: N88BE3D6589EN

Abstracts

Gain new KOL insights on the latest events happening in non-small cell lung cancer (NSCLC), including: the EU approval of Novartis’s Mekinist (trametinib) in combination with Tafinlar (dabrafenib) for the treatment of BRAF V600-positive advanced NSCLC; Takeda's Alunbrig (brigatinib) being granted accelerated approval in the US for the treatment of patients with metastatic ALK-positive NSCLC who have progressed on or are intolerant to Xalkori (crizotinib; Pfizer); the Phase III ALEX study demonstrating Roche’s Alecensa (alectinib) to be superior to Xalkori in terms of progression-free survival (PFS) in the first-line treatment of ALK-positive NSCLC; and AbbVie’s PARP inhibitor, veliparib, failing to meet its primary endpoint of overall survival (OS) in a Phase III trial in NSCLC.

Business Questions

How do KOLs view the EU approval of Novartis’s Mekinist in combination with Tafinlar for the treatment of BRAF V600-positive advanced NSCLC?

Where do KOLs see Mekinist plus Tafinlar fitting into the NSCLC treatment algorithm?

What factors could curtail the use of Mekinist in combination with Tafinlar?

How do KOLs view the US approval of Takeda's Alunbrig and data from the ALTA trial?

Where will Alunbrig be best positioned in the NSCLC treatment algorithm?

How do KOLs view the positive outcome from the ALEX trial of Roche’s Alecensa and what will determine its success in first-line therapy?

+357 96 030922
info@marketpublishers.com

To what extent will Alecensa be used in the first-line treatment of ALK-positive NSCLC?

How is the second-line treatment of ALK-positive NSCLC likely to evolve in light of recent events?

How do KOLs view the Phase III failure of AbbVie’s veliparib and the future of PARP inhibitors in NSCLC?

+357 96 030922
info@marketpublishers.com

I would like to order

Product name: NSCLC [2016]: Bulletin #3

Product link: https://marketpublishers.com/r/N88BE3D6589EN.html

Price: US$ 1,045.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/N88BE3D6589EN.html